FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies
B. Li, Leena Gandhi, Benjamin Besse, Komal Jhaveri, Julien Mazières, Valentina Boni, Geoffrey I. Shapiro, Saiama N. Waqar, Santiago Viteri, H. Park, David I. Quinn, Salomon M. Stemmer, Alexis B. Cortot, Mark E. Burkard, Maurizio Scaltriti, Helen Won, Alshad S. Lalani, Leanne McCulloch, Judith D. Bebchuk, Feng Xu, Richard Bryce, Funda Meric‐Bernstam, Sarina A. Piha‐Paul, David B. Solit, Pasi A. Jänne
Topics & Concepts
NeratinibMedicineLung cancerCancer researchMutantTrastuzumabTyrosine-kinase inhibitorTemsirolimusCarcinogenesisPI3K/AKT/mTOR pathwayCancerOncologyInternal medicineBreast cancerSignal transductionBiologyGeneticsGeneDiscovery and development of mTOR inhibitorsLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research